|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.39 CHF | -2.05% |
|
-5.97% | +14.83% |
MarketScreener Strategies
Search
 | Sandoz: Remarkable biosimilar performance runs the show | April 29, 2026 at 09:53 pm IST |
 | Top-of-the-class valuation for Sandoz | March 04, 2026 at 07:01 pm IST |
| Sandoz: Healthy 2026 outlook raises hopes for a mid-term guidance upgrade | February 25, 2026 at 07:15 pm IST |
| Sandoz: Growth prospects that even some Big Pharmas may envy | February 16, 2026 at 07:06 pm IST |
 | Sandoz lifts target price on biosimilar momentum | November 21, 2025 at 06:45 pm IST |
 | Sandoz has significant clinical visibility | August 08, 2025 at 01:18 pm IST |
 | Sandoz: Already back to its highs | June 23, 2025 at 12:51 pm IST |
 | Sandoz sues Amgen in the US | April 14, 2025 at 08:02 pm IST |
 | Sandoz keeps its ambitions intact | March 06, 2025 at 02:10 pm IST |
 | Sandoz: Ready to unleash its full potential on its own | June 26, 2024 at 09:58 pm IST |
No results match your criteria
Filters
- Stock Market
- Stocks
- SDZ Stock
- News Sandoz Group AG
- MarketScreener Strategies
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition